Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$615K Sell
1,699
-325
-16% -$111K 0.18% 59
2026
Q1
$712K Buy
2,024
+10
+0.5% +$3.56K 0.24% 52
2025
Q4
$659K Hold
2,014
0.21% 55
2025
Q3
$568K Hold
2,014
0.19% 58
2025
Q2
$562K Buy
2,014
+38
+2% +$10.8K 0.21% 55
2025
Q1
$616K Buy
1,976
+2
+0.1% +$591 0.25% 49
2024
Q4
$515K Sell
1,974
-18
-0.9% -$5.34K 0.21% 50
2024
Q3
$642K Sell
1,992
-22
-1% -$7.2K 0.26% 45
2024
Q2
$629K Hold
2,014
0.28% 40
2024
Q1
$625K Buy
2,014
+31
+2% +$9.07K 0.29% 40
2023
Q4
$577K Hold
1,983
0.29% 42
2023
Q3
$533K Hold
1,983
0.33% 31
2023
Q2
$440K Hold
1,983
0.27% 40
2023
Q1
$479K Hold
1,983
0.31% 33
2022
Q4
$521K Buy
1,983
+718
+57% +$192K 0.36% 29
2022
Q3
$285K Sell
1,265
-13
-1% -$3.15K 0.21% 43
2022
Q2
$311K Sell
1,278
-20
-2% -$4.9K 0.22% 47
2022
Q1
$314K Buy
1,298
+20
+2% +$4.59K 0.19% 50
2021
Q4
$288K Buy
1,278
+13
+1% +$2.74K 0.17% 53
2021
Q3
$269K Hold
1,265
0.17% 56
2021
Q2
$308K Hold
1,265
0.19% 49
2021
Q1
$315K Buy
1,265
+1,253
+10,442% +$299K 0.21% 47
2020
Q4
$294K Buy
+12
New +$2.77K 0.21% 48

Other funds holding AMGN

Goepper Burkhardt's AMGN Position: Q2 2026 in Review

Goepper Burkhardt reduced its Amgen (AMGN) stake by 16% in Q2 2026, selling an estimated $111K and leaving 1,699 shares worth $615K. The position accounts for 0.18% of the portfolio, ranked #59.

Goepper Burkhardt first reported a position in AMGN in Q4 2020 and has held it in 23 quarters since. The position peaked at $712K in Q1 2026. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Goepper Burkhardt held 1,699 shares of Amgen worth $615K as of Q2 2026.
  • Goepper Burkhardt sold 325 Amgen shares in Q2 2026, an estimated $111K.
  • Amgen made up 0.18% of Goepper Burkhardt's portfolio in Q2 2026, its #59 holding.
  • Goepper Burkhardt first reported a position in Amgen in Q4 2020 and has held it in 23 quarters since.
  • Goepper Burkhardt's Amgen position peaked at $712K in Q1 2026.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Goepper Burkhardt's 13F filing for Q2 2026, filed 10 Aug 2026.